Skip to main content
. 2019 May 13;12(7):951–958. doi: 10.1016/j.tranon.2019.04.001

Figure 2.

Figure 2

Antitumor efficacy of Vemurafenib in vivo. Melmet-382 PDX was treated with Vemurafenib (50 mg/kg) given twice daily by oral gavage for 14 days. Control mice were given 10% DMSO in 0,5% methylcellulose orally. Tumor volume was measured twice a week and results presented as relative volume related to tumor volume at initiation of the treatment. Error bars represent ±S.E.M.